Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus BETAXON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus BETAXON.
BETAXOLOL HYDROCHLORIDE vs BETAXON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
10-20 mg orally once daily; maximum 20 mg/day.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Category C
Category C
Beta-Blocker
Beta-Blocker